

Editorial for journal of molecular oncology research.

Yufeng Peg*

US Food and Drug Administration (FDA), Silver Spring, MD, USA

Accepted on November 25, 2020

Editorial

The Journal of Molecular Oncology Research (JMOR) is an international, rapid peer reviewed journal that encourages and supports good quality and genuine original research, systematic reviews, meta-analyses and technology reports, perspectives on all disciplines and therapeutic areas within the specialty [1].

The journal aims to research on wide spectrum of findings related to therapeutic advances in cancer treatment, molecular phenotypes, tumor diagnosis, cancer genetics, epigenetics, genomic instability, tumor immunology, chemotherapy, radiotherapy, and surgery. The main aim for publication is to establish a novel opinion of molecular significance in diagnosis, prognosis, and prevention strategies for cancer patients.

This multidisciplinary open access journal ensures widespread dissemination of research work as original Research Articles, Review Article, Case Reports, Short Communication, Opinion Articles and Letter to Editor.

The journal focuses on molecular analysis that provides novel mechanisms that describe pathways and processes related to cancer risk, development, and/or progression. The journal intensifies on all cancer-correlated pathways including cell-cycle regulation, cell death, chromatin regulation, DNA damage DNA repair, gene, RNA regulation, genomics, oncogenes and tumor suppressors' genes.

Journal of molecular oncology research provides a predominant gathering for innovative discoveries in cancer-connected research, presenting an unparalleled valuable chance to interface and transmit knowledge to specialists and the public globally. The online appearance of Molecular oncology research allows the immediate publication of accepted articles and the presentation of large amounts of data and supplemental information to ensure that new research is disseminated as efficiently and quickly as possible to the scientific community [2].

Benefits of publishing in our journal

Molecular oncology research open access policy allows maximum visibility of articles published in the journal as they are accessible to a wide, global audience.

Molecular oncology research endeavors a fast publication agenda at the time of maintaining rigorous peer review all articles to be submitted via online, and peer review is handled and guided fully electronically. Articles will be published with their final citation after acceptance, in both fully browsable HTML format, and as a formatted PDF [3].

Articles published in our journal are included in article alerts and regular email updates. Some may be highlighted on Molecular oncology research homepages [4].

In addition, articles published in Molecular oncology research may be promoted using twitter and other social networking pages. These activities increase the exposure and number of accesses for articles published in Molecular oncology research [5].

Conclusion

I thank all reviewers for their excellent contributions. At this stage we are calling for submissions of articles, commentaries, and letters to the editor for the upcoming issues. We glance forward to receiving your exciting contribution. Finally, I would like to thank you, the contributors and readers for your interest in the journal and I encourage you to continue to send us your valuable feedback and ideas for further improvement of our journal.

References

1. MLitos I, Maragkouli E, Papadopoulos V et al. Growing teratoma syndrome presented as a left forearm mass: A case report. *J Mol Oncol Res.* 2018;2(3):45-47.
2. Trivedi T, Tankshali R, Jetly D et al. SCCAg mRNA expression predicts early relapse in histopathologically negative lymphnodes of oral squamous cell carcinoma patients. *J Mol Oncol Res.* 2018;2(3):48-58.

3. Sharma J, Deb B, Kumar P. Developments in the area of bladder cancer genomics and its importance in the treatment selection *J Mol Oncol Res.* 2018;2(3):58-62.
4. Ozkan AD, Kaleli HN, Kaleli S. A key receptor in apoptosis: Toll-like receptor 3 (TLR3) *J Mol Oncol Res.* 2018;2(3):63-67.
5. Jain K, Bapna A, Somani N, et al.. Efficacy and safety of pemetrexed and cisplatin chemotherapy as first line in advanced stage of lung adenocarcinoma. *J Mol Oncol Res.* 2018;2(3):1-6.

***Correspondence to:**

Yufeng Peg
US Food and Drug Administration (FDA)
Silver Spring,
MD, USA
E-mail: yufeng.peg@fda.edu